Generex Biotechnology Corporation (NASDAQ: GNBT) announced today that on March 1, 2006 the Company concluded a positive Pre-New Drug Submission (NDS) meeting with the Regulatory Affairs Division of the Biologics and Genetic Therapeutics Directorate of Health Canada in respect of Generex Oral-lyn™, the Company’s proprietary oral insulin spray product for the treatment of diabetes.
